Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
Puma Biotechnology, Inc. reported that Alan H. Auerbach’s warrant to purchase 2,116,250 shares at $16.00 per share expired unexercised on October 4, 2026. Auerbach, the company’s President, Chief Executive Officer and a director, beneficially owned 8,648,958 shares, or approximately 16.0%, based on 51,698,356 shares outstanding as of October 5, 2026. His reported holdings included 6,400,295 shares held directly, 1,556,721 shares issuable upon exercise of options, and 691,942 shares issuable upon vesting of restricted stock units; the options and restricted stock units were exercisable or due to vest within 60 days of October 4, 2026.
PUMA BIOTECHNOLOGY, INC. (PBYI) director Troy Edward Wilson reported selling 5,000 shares of Common Stock on September 14, 2026 at $9.10 per share in an open-market or private transaction made under a Rule 10b5-1(c) trading plan adopted on June 15, 2026. Following this sale, he holds 54,750 shares directly and additional indirect holdings of 400 shares for one child and 150 shares for another child.
PUMA BIOTECHNOLOGY, INC. (PBYI) director Alessandra Cesano reported an option exercise and share sale on September 14, 2026. She exercised 50,000 stock options for common stock at an exercise price of $2.93 per share, receiving 50,000 common shares. On the same date, she sold 62,150 common shares at a weighted average price of $9.123 per share in multiple transactions within a $9.03–$9.20 range. The filing states these sales were made under a Rule 10b5-1(c) trading plan adopted on June 15, 2026, and the stock option reported as exercised is fully vested and expires on July 28, 2032.
PUMA BIOTECHNOLOGY, INC. (PBYI) is the issuer for a planned resale of its common stock under Rule 144 by director Alessandra Cesano. The notice covers up to 62,150 shares, including 12,150 shares from restricted stock that vested on June 11, 2025 and 50,000 shares issuable from a stock option exercise dated September 14, 2026. The shares are held at Fidelity Brokerage Services LLC and are listed on NASDAQ.
PUMA BIOTECHNOLOGY, INC. (PBYI) has a notice of proposed sale under Rule 144 by director Troy Edward Wilson. The filing covers a planned sale of 5,000 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $45,500.00, and a proposed sale date of September 14, 2026. The shares relate to restricted stock vesting recorded as compensation from June 11, 2025.
Puma Biotechnology, Inc. reported Q2 2026 total revenue of $56,502 (thousands), up from $52,436 (thousands) a year earlier, driven by product revenue of $53,560 (thousands) and royalty revenue of $2,942 (thousands). Q2 net income was $8,189 (thousands), compared with $5,855 (thousands) in Q2 2025, with diluted EPS of $0.16.
For the first six months of 2026, revenue was $101,316 (thousands) and net income was $4,436 (thousands). As of June 30, 2026, total assets were $192,736 (thousands), including cash, cash equivalents and marketable securities totaling approximately $93.9 million, and stockholders’ equity was $138,544 (thousands). Long-term debt was reduced to $0 after repayment of the Athyrium Notes, while the company continues to commercialize NERLYNX® and develop alisertib. Management believes existing liquidity and expected cash flows are sufficient to meet operating needs for at least one year after this Form 10-Q is filed, while noting potential uncertainty from new U.S. pharmaceutical import tariffs.
Puma Biotechnology reported results for the quarter ended June 30, 2026 and raised its 2026 revenue and net income guidance, citing increased demand for NERLYNX. Total revenue for the quarter was $56.5 million, including NERLYNX net product revenue of $53.6 million, up from $52.4 million and $49.2 million in the prior-year quarter. GAAP net income rose to $8.2 million, or $0.16 per basic and diluted share, from $5.9 million, while non-GAAP adjusted net income increased to $10.1 million.
For the first six months of 2026, total revenue was $101.3 million and GAAP net income was $4.4 million, down from $8.8 million, as operating costs grew to support alisertib clinical programs; R&D expenses rose to $38.7 million from $29.3 million. Cash, cash equivalents and marketable securities were $93.9 million at June 30, 2026, and outstanding debt was reduced to zero after the final payment under the 2021 Note Purchase Agreement. The company now guides 2026 total revenue to $224–$231 million and net income to $17–$20 million, and highlights multiple upcoming milestones in its ALISCA alisertib Phase II trials in breast and small cell lung cancer.
Puma Biotechnology President and CEO Alan H. Auerbach reported an open-market sale of 44,058 shares of common stock at $8.263 per share on July 6, 2026. After this transaction, he still directly holds 7,261,671 shares, suggesting it represents a small portion of his stake. The sale was executed under a pre-established Rule 10b5-1(c) sell-to-cover program adopted on December 17, 2020, indicating it was part of a pre-planned trading arrangement.
PUMA Biotechnology officer Douglas M. Hunt reported an open-market sale of company stock. On the reported date, he sold 8,460 shares of PUMA Biotechnology common stock at an average price of $8.263 per share. After this transaction, he directly holds 196,841 shares of common stock. The filing notes that the sale occurred under a Rule 10b5-1(c) sell-to-cover program adopted on December 14, 2020, indicating the trade was executed pursuant to a pre-arranged trading plan.
PUMA Biotechnology Chief Financial Officer Maximo F. Nougues sold 9,386 shares of common stock on July 6, 2026 in an open-market transaction at an average price of $8.263 per share. After this sale, he directly holds 230,637 shares of the company’s common stock.
The transaction was executed under a pre-arranged Rule 10b5-1(c) sell-to-cover program, originally adopted on December 14, 2020, indicating it followed a preset trading plan rather than discretionary market timing.